NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioStem Technologies, Inc. (BSEM) Stock Analysis

BioStem Technologies, Inc. (BSEM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BSEM

$1.68

+$0.04 (+2.44%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BSEM with… →

BSEM Key Statistics

As of Oct 21, 2026
Trading
Open
$1.62
Previous Close
$1.64
Day's Range
1.55–1.78
52-Week Range
2.13–8.40
Volume
197.22K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
$42.01M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
7.76
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.21
Financials (FY)
Revenue (FY)
$301.83M+1,708.93%
Net Income (FY)
$31.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
−81.80%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
18.67M
1-Year Return
−68.36%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
124.56K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BSEM closed at $1.68, −68.36% over 1 year.

BioStem Technologies, Inc. (BSEM) has a market capitalization of $42.01M.

In fiscal 2024, BSEM reported revenue of $301.83M.

BSEM Stock Return by Calendar Year

BioStem Technologies, Inc. (BSEM) 10-year return: what $10,000 became

1 year
$10,000 $3,164
−68.36%
5 years
$10,000 $11,667
+16.67%
10 years
$10,000 $2,240
−77.60%

If you had invested $10,000 in BioStem Technologies, Inc. (BSEM) 10 years ago, at the close on October 21, 2016, it would have been worth $2,240 at the close on October 21, 2026: −77.60% in total, −13.90% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−55.91%
2025−72.47%
2024+136.18%
2023+95.99%
2022+187.50%
2021−28.28%
2020−42.00%
2019−21.88%
2018−73.33%
2017+19.40%
2016 (partial year)−28.21%

As of October 21, 2026.

BSEM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2024$301.83M$31.88M10.6%
2023$16.69M−$8.48M−50.8%
2022$6.88M−$7.19M−104.6%
2021$4.34M−$1.45M−33.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$301.83M$288.08M$31.20M$31.88M10.6%
2023$16.69M$15.42M−$7.78M−$8.48M−50.8%
2022$6.88M$5.99M−$4.68M−$7.19M−104.6%
2021$4.34M$2.87M−$1.61M−$1.45M−33.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2024.

BSEM Valuation vs Biotechnology Median

Median of 608 stocks
MetricBSEMBiotechnology medianvs median
P/S ratio1.2113.300.1x the median
Profit margin−81.80%−38.31%43.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioStem Technologies, Inc. (BSEM) carries a market capitalisation of $42.01M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

BSEM last closed at $1.68 on October 21, 2026. That is +$0.04 (+2.44%) against the previous close. Over the past 52 weeks the price has ranged from $2.13 to $8.40.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $301.83M. That is +1,708.93% against the prior fiscal year, when revenue was $16.69M. The same year closed with net income of $31.88M. Profit margin runs at −81.8%. That is 43.5 percentage points below the Biotechnology median of −38.31%.

Across the 4 fiscal years on file, revenue moves from $4.34M in 2021 to $301.83M in 2024. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 7.76. The price-to-sales ratio is 1.21. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −68.36%. Measured over 10 years, that is −13.90% a year compounded. The reported beta is 0.5. Daily returns over the trailing 10 years annualize to a volatility of 147.31%.

Growth & Income

No dividend is on file for BSEM.

So far in 2026 the total return is −55.91%. The strongest complete calendar year on file is 2022 at +187.50%; the weakest is 2018 at −73.33%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

BioStem Technologies, Inc. (BSEM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioStem Technologies, Inc. BSEM $42.01M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioStem Technologies, Inc.

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Visit website →